Invesco Ltd. reduced its position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 60.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 391,163 shares of the company's stock after selling 596,434 shares during the period. Invesco Ltd. owned about 0.97% of RxSight worth $13,448,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in RxSight by 4.2% in the fourth quarter. Vanguard Group Inc. now owns 2,383,548 shares of the company's stock valued at $81,946,000 after purchasing an additional 96,464 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of RxSight by 32.6% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,551,620 shares of the company's stock valued at $53,345,000 after buying an additional 381,389 shares during the period. Geode Capital Management LLC grew its position in shares of RxSight by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 830,758 shares of the company's stock worth $28,568,000 after buying an additional 13,641 shares in the last quarter. DF Dent & Co. Inc. purchased a new stake in shares of RxSight during the fourth quarter worth approximately $14,524,000. Finally, Thrivent Financial for Lutherans raised its holdings in RxSight by 53.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 352,626 shares of the company's stock valued at $12,124,000 after acquiring an additional 122,989 shares in the last quarter. 78.78% of the stock is owned by institutional investors and hedge funds.
RxSight Trading Up 0.3 %
Shares of RxSight stock traded up $0.04 during trading on Friday, reaching $14.77. The company's stock had a trading volume of 512,239 shares, compared to its average volume of 778,889. The firm has a market cap of $597.97 million, a PE ratio of -17.79 and a beta of 1.26. The company has a 50-day moving average price of $22.46 and a two-hundred day moving average price of $34.20. RxSight, Inc. has a fifty-two week low of $13.50 and a fifty-two week high of $66.54.
RxSight (NASDAQ:RXST - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The company had revenue of $40.21 million during the quarter, compared to analyst estimates of $40.23 million. On average, analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current fiscal year.
Insider Activity at RxSight
In related news, Director Tamara Fountain sold 7,000 shares of RxSight stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the sale, the director now directly owns 24,793 shares in the company, valued at $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 9.36% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of brokerages have commented on RXST. Wells Fargo & Company dropped their price objective on shares of RxSight from $35.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 3rd. Needham & Company LLC restated a "buy" rating and issued a $43.00 price target on shares of RxSight in a research note on Thursday, April 3rd. Piper Sandler started coverage on RxSight in a research report on Tuesday, April 15th. They set a "neutral" rating and a $18.00 price objective for the company. Stifel Nicolaus cut their target price on RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Finally, UBS Group cut RxSight from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $45.00 to $16.00 in a research note on Wednesday, April 9th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $37.60.
Check Out Our Latest Stock Report on RXST
About RxSight
(
Free Report)
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Further Reading
Before you consider RxSight, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.
While RxSight currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
